Navigation Links
New drug target for immune diseases discovered
Date:8/3/2010

gerated production of molecules that activate the adaptive immune system and abnormal antibodies, which attack normal cells causing inflammation and tissue damage. This exaggerated production may occur partly as a result of abnormally strong signaling from TACI via MyD88. By analyzing cells and tissues from immunodeficient patients and genetically engineered mice, Dr. Cerutti's team found a previously unknown interaction between TACI and MyD88 that is important for the production of antibodies against infectious agents. Yet, the same interaction may cause the exaggerated immune response in people with autoimmune diseases.

"Our discovery provides a novel specific target, the signaling pathway between TACI and MyD88, to block the overreaction of the immune system and tissue damage in individuals with autoimmune disorders," said Dr. Cerutti. "We look forward to studying this discovery further and developing therapeutic targets that will inhibit the interaction between TACI and MyD88, preventing autoimmune diseases from progressing with fewer side effects than currently prescribed treatments."

Dr. Cerutti's team collaborated with other researchers at Mount Sinai School of Medicine, including Charlotte Cunningham-Rundles, MD, Professor of Medicine and Pediatrics, and Huabao Xiong, PhD, Assistant Professor of Medicine.

According to the National Women's Health Information Center, autoimmune diseases impact 23.5 million Americans. Common examples include lupus, in which the immune system attacks the skin and/or several organs within the body; rheumatoid arthritis, in which the immune system attacks joints; multiple sclerosis, in which the immune system attacks the nervous system; and Type 1diabetes, in which the immune system attacks insulin-producing cells in the pancreas.


'/>"/>

Contact: Mount Sinai Press Office
newsnow@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. MSU targets womens health research with $2.5 million grant
2. NYU Langone offers vascular-targeted photodynamic therapy for localized prostate cancer
3. Researcher targets gene regulators on link between arsenic, cancer
4. Success of community interventions for childhood obesity varies depending on the target age group
5. Radiation device allows for targeted breast radiation to control cancer
6. Targeting flight-or-fight hormone response to combat heart failure
7. Miami meeting on radiation therapy targets patient safety
8. EcoFocus Study Identifies Opportunities for Companies to Target the New 21st Century Mom
9. Surveillance colonoscopy should be targeted to high-risk patients
10. Targeting disease remission has socio-economic benefits over low disease activity
11. Tumor target suggests personalized treatment for melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 03, 2015 Johnson & Johnson and ... million to resolve a Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) ... company allegedly used to market the antipsychotic drug. ... that the Arkansas Attorney General moved to dismiss the ... The Risperdal settlement amounts to just a fraction of ...
(Date:6/3/2015)... June 03, 2015 “ Harmony ” was ... takes a look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... that wants to improve some aspect of their life. , ... only for people with difficulties in their life. However, hypnotherapy ...
(Date:6/3/2015)... 2015 Follow us on LinkedIn ... revolutionized disease treatment on account of their better mode ... such as rheumatoid arthritis. The industry is expected to ... small molecule drugs to biopharmaceuticals over the coming years. ... and gene therapies, and recombinant proteins has attracted industry ...
(Date:6/3/2015)... On the heels of a report predicting ... 2020 ( click here to review news coverage about ... Baltimore has the talent to become a world-leading center ... and other biological data are collected and analyzed to help ... all the elements of a perfect storm for bioinformatics leadership,” ...
(Date:6/3/2015)... Dr. Steven Reisman, a nationally recognized cardiologist and ... ) located in NYC, announced today the expansion of same ... most cases, depending on the level of care a patient ... will be seen by a cardiologist that same day. , ... to ensure that people who have an urgent need to ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:An Application to Enjoy Hypnotherapy Sessions at Home was featured on NewsWatch Television 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2
... says , WEDNESDAY, Jan. 20 (HealthDay News) -- Heart and ... mild cases of chronic lung disease affect the heart,s ability ... that a larger subset of heart failure may be due ... professor of medicine and epidemiology at Columbia University Medical Center ...
... 3 fewer grams a day slashed heart disease, death rates ... just 3 grams a day -- the equivalent of half a ... death in U.S. adults, researchers claim. , According to the authors ... New England Journal of Medicine , the projected reductions would ...
... , WASHINGTON , Jan. 20 ... Tony Perkins released the following statement regarding the ... "For a Senate seat considered to be in the left-hand column ... nearly revolutionary. President Obama,s desperate visit to the Bay State ...
... Implications of Federal Medicare Cuts Require Careful Scrutiny and ... , AUSTIN, Texas , Jan. 20 ... Tim Graves , today expressed concern about the growing cumulative ... preserve and protect Texas, most vulnerable nursing home ...
... researchers at Rush University Medical Center have found three ... to social rejection. The studies are a crucial step ... for social-emotional learning difficulties. The results from the studies ... and Adolescent Psychology . Findings from the ...
... in human cells has singled out a molecule that ... produce an allergic response. The signaling molecule, called thymic ... allergic diseases such as asthma, atopic dermatitis (eczema) and ... Liu, M.D., Ph.D., at the University of Texas M.D. ...
Cached Medicine News:Health News:Even Mild Lung Disease Affects the Heart 2Health News:Small Cuts in Salt Intake Spur Big Drops in Heart Trouble 2Health News:Small Cuts in Salt Intake Spur Big Drops in Heart Trouble 3Health News:FRC: Mass Election Results a Near Revolutionary Rejection of President Obama's Leftist Agenda 2Health News:Texas Health Care Association: Meeting Texas Seniors' Ongoing Care Needs Threatened by Looming State, Federal Funding Threats 2Health News:3 key factors to help children avoid social rejection identified 2
(Date:6/3/2015)... , June 02, 2015 Research and ... of the "The Future of Pharmaceutical Outsourcing" ... they are in a desperate need to develop ... cost, drug companies have been increasingly utilizing external ... productivity while constantly streamlining their internal operation. Their ...
(Date:6/3/2015)... SHANGHAI , June 3, 2015 MEDTEC China South ... an extension of MEDTEC China 2015, MEDTEC China South has ... attributes, standing out as a key event for the medical ... After many years of challenges, this year marks the successful return ... 10 years after the event first debuted there in 2005. ...
(Date:6/3/2015)... , June 3, 2015 Genoa ... Pharmaceuticals, Inc., bringing together two pharmacy organizations with proven ... illness. Both companies have strong reputations for outstanding customer ... Genoa is the ... health community and those affiliated with managing the cost ...
Breaking Medicine Technology:The Future of Pharmaceutical Outsourcing: 2015 Report 2MEDTEC Successfully Returns to Southern China 2MEDTEC Successfully Returns to Southern China 3Genoa, a QoL Healthcare Company Acquires Northeast Pharmaceuticals, Inc. 2
... , MORRISTOWN, N.J. , March 11 ... today announced the U.S. Food and Drug Administration (FDA) ... suspension), a new twice-yearly formulation of TRELSTAR®, a proven, ... With an anticipated May launch, TRELSTAR® 22.5 mg is ...
... , THOUSAND OAKS, Calif. , March 11 ... has received a US Patent Office Notice of Allowance ... expressing, secreting, and purifying the NELL-1 sequence of the ... a Chinese hamster ovary (CHO) cell. This patent continues ...
Cached Medicine Technology:FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process 2Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process 3
... The Hoffmann® II Compact™ Upper extremity fixator ... of the distal radius by allowing independent ... One of the main goals has been ... providing total versatility and ease of use. ...
The Small External Fixator has straight or angled frames, independent pin placement, and combines easily with Large and Medium External Fixator frames....
... Fixator is now available in a convenient, ... instrumentation. The surgical technique is printed on ... , ,This fixator allows the surgeon to ... multipaner adjustments in the frame via joints ...
... Fixation System for distal radius fractures allows ... length and rotation. The unique wrist lock ... into extension without losing fracture reduction. Post-op ... the surgeons office. Priced competitively and sold ...
Medicine Products: